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Atrial ﬁbrillation is now recognized as a signiﬁcant medical and social problem. Atrial ﬁbrillation not
only causes cardiovascular complications, including thromboembolism and heart failure, but also
decreases the survival of patients with impaired left ventricular function; thus, it is considered
an independent factor for cardiovascular death. The goal of antiarrhythmic drug therapy for atrial
ﬁbrillation is improvement of daily quality of life and cardiovascular prognosis in maintaining sinus
rhythm, while ensuring the safety of antiarrhythmic drugs. Antiarrhythmic drugs are prescribed to
prevent recurrence of atrial ﬁbrillation; however, they demonstrate limited efﬁcacy. Recently, catheter
ablation has been established as a promising new therapy to prevent recurrence of atrial ﬁbrillation,
even though this procedure would be difﬁcult to apply clinically because of its complications and the
large number of patients requiring treatment. Since the antiarrhythmic drugs remain the ﬁrst-line,
primary therapy for paroxysmal atrial ﬁbrillation, clinicians should select appropriate antiarrhythmic
drugs for treatment of paroxysmal atrial ﬁbrillation based on individual patient characteristics.
Herein, I review the current strategies of antiarrhythmic drug therapy for paroxysmal atrial
ﬁbrillation from the point of view of pharmacological prevention of atrial ﬁbrillation recurrence,
improvement of patient quality of life, and cardiovascular prognosis.
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1.1. Indications for rhythm control therapy
Various factors are involved in the development of atrial ﬁbrilla-
tion (AF), including the condition of the autonomic nervous system,
underlying heart disease, hemodynamic disorders, inﬂammation,rt Rhythm Society. Published by E
01.endocrine disorders, electrolyte imbalance, oxidative stress, and
concomitant drug use. The speciﬁc factors that affect the develop-
ment of AF and the extent of their effects differ among patients. It is
important to investigate the possible causes of AF, which manifests
across a wide variety of clinical proﬁles, in order to understand the
pathophysiology of this condition and to determine treatment
strategies for individual patients.
Generally, rhythm control therapy using antiarrhythmic drugs
is positively indicated for (1) patients with severe subjective
symptoms negatively affecting quality of life (QOL); (2) patients
with paroxysmal AF; (3) patients with without or with mildlsevier B.V. All rights reserved.
T. Komatsu / Journal of Arrhythmia 28 (2012) 162–169 163underlying heart disease; (4) patients without or with slight
(o50 mm) increase in left atrial dimension; and (5) patients in
whom AF causes an abrupt disturbance of hemodynamics or
acute worsening of myocardial ischemia. On the other hand, rate
control therapy is indicated for (1) asymptomatic patients and
those with subjective symptoms having little or no effect on QOL;
(2) patients with permanent AF; and (3) patients with a signiﬁ-
cant increase in left atrial dimension (Z50 mm).
1.2. Examinations required prior to rhythm control therapy
Patients should undergo chest X-ray, standard 12-lead elec-
trocardiogram (ECG), blood examination, transthoracic echocar-
diography, ambulatory 24-h ECG monitoring, exercise ECG, brain
computed tomographic (CT) examination or magnetic resonance
imaging (MRI), and other appropriate tests prior to the initiation
of treatment. Table 1 summarizes the key points to be examined
in these tests. Patients with hepatic and/or renal dysfunction
should be treated with drugs that do not negatively affect the
metabolic pathways of antiarrhythmic drugs. Patients with elec-
trolyte imbalances such as hypokalemia and hypocalcemia are
prone to proarrhythmic adverse effects from antiarrhythmic
drugs. Since the metabolism and excretion of antiarrhythmic
drugs are slow and blood concentrations of these drugs tend toTable 1
Examinations required prior to rhythm control therapy.
I. Chest radiography
Cardiomegaly, pulmonary congestion, hydrothorax, underlying heart
diseaseunderlying pulmonary disease, etc.
II. Standard 12-lead electrocardiography
Heart rate, PQ interval, QRS duration QT interval, ST-T change, etc.
III. Blood examination
Renal and liver function, electrolyte, serum concentration of antiarrhythmic
drug, atrial naturiuretic peptide, brain naturiuretic peptide, D-dimer,
prothrombin time- international normalized ratio, etc.
IV. Transthoracic or transesophageal echocardiography
Underlying heart disease, cardiac function, enlarged right or left atrium,
intracardiac thrombus, spontaneous echo contrast, velocity of left
appendage or pulmonary vein, aortic atheroma, etc.
V. Ambulatory 24-hr monitoring
Phramacological evaluation, rate control, sick sinus syndrome or
asymptomatic atrial ﬁbrillation, etc.
VI. Treadmill or ergometer exercise test
Myocardial ischemia, provocation of arrhythmia, rate control, etc.
VII. Computed tomographic examination / magnetic resonance image
Ischemic or hemorrhagic stroke, etc.
Table 2
Pharmacokinetics, effective blood concentrations, and excretion me
ﬁbrillation. (The description order of antiarrhythmic drugs follow th
for atrial ﬁbrillation. J Arrhythmia 2005; 21: 358–370.)
Antiaarhythmic drugs Cmax (h) T1/2 (h)
Qunidine 1–4 6–8
Procaineamide 0.5–1.0 3–5
Disopyramide 2 4–8
Cibenzoline 1.5 5–6
Pirmenol 1.0–1.5 8–10
Lidocaine – 13 min
Mexiletine 2–4 8–16
Aprindine 2–4 9–27
Flecainide 2–4 12–27
Propafenone 2–3 2–10
Pilsicainide 1–2 4–5
Amiodarone 3–7 26–107 days
Sotalol 2–4 7–11
Verapamil 2 3–7
Bepridil 3.1 80
Adenosine triphosphate 2–3 s 10 sincrease in elderly patients, physicians must carefully select and
modify the maintenance doses of antiarrhythmic drugs and the
type of drugs used concomitantly. Table 2 lists the antiarrhythmic
drugs currently available in Japan, their pharmacokinetics, their
effective blood concentrations, and excretion mechanism.2. Preventive efﬁcacy of antiarrhythmic drugs
2.1. Efﬁcacy in maintaining sinus rhythm in patients with paroxysmal
AF (patients with episodes of AF that terminate spontaneously within
7 day)
2.1.1. Results of studies in Western countries
In Western countries, the percentage of patients who main-
tained sinus rhythm after treatment with the Class I antiarrhyth-
mic agent ﬂecainide (100–300 mg/day) was 61–71% after
6 months of treatment [1–3] and 62–77% after 12 months [3–5].
The corresponding percentage in patients receiving the Class I
agent propafenone (450–1,200 mg/day), was 57% after 6 months
[6] and 45–55% after 12 months [4–8]. For Class III drugs, the
corresponding percentages were 46–50% [9,10] and 37–70% [8,10]
after 6 and 12 months of treatment with sotalol, respectively
(160–690 mg/day), and 50–80%[11–13] after 12 months of treat-
ment with amiodarone (200–300 mg/day).
Recently, the Canadian Trial of Atrial Fibrillation (CTAF), a large
randomized study comparing the efﬁcacy of Class I and III drugs
in preventing recurrent AF [14], reported that the percentage
of patients with no AF recurrence after 12 and 24 months of
treatment were 66% and 51%, respectively, in those treated with
amiodarone (mean dosage: 186748 mg/day). These percentages
were higher than those of propafenone (45% and 37%, respec-
tively; mean dosage 4717121 mg/day) and sotalol (48% and 34%,
respectively; mean dosage 224783 mg/day; Fig. 1). In a sub-
analysis of the Atrial Fibrillation Follow-up Investigation of
Rhythm Management (AFFIRM) study, the percentage of patients
without recurrence of AF at a 12-month follow-up were 62%, 38%,
and 23% for those treated with amiodarone, sotalol, and Class I
drugs, respectively, demonstrating that amiodarone was the most
effective drug for preventing AF recurrence [15]. Regarding
dronedarone (400 mg/day), a new agent recently approved in
Western countries, it has been reported that the percentages of
patients with paroxysmal AF or persistent AF who maintained
sinus rhythm after 6 and 12 months of treatment were 50–64%
and 35–40%, respectively (Fig. 2) [16,17]. However, a meta-chanism of antiarrhythmic drugs used for treatment of atrial
at of Sugi K, Noro M, Sakata T, et al. Pharmacological treatment
Therapeutic levels (mg/ml) Excretion (%)
2–5 Liver(80) Kidney(20)
4–12 Liver(40) Kidney(60)
2–5 Liver(40) Kidney(60)
0.3–1.0 Liver(20) Kidney(80)
0.4–1.0 Liver(30) Kidney(70)
1–5 Liver(90) Kidney(10)
0.75–2.0 Liver(90) Kidney(10)
0.25–1.25 Liver (100)
0.2–1.0 Liver(15) Kideny(85)
0.2–1.0 Liver(90) Kidney(10)
0.2–1.0 Kidney(100)
1.0–2.0 Liver (100)
1–3.2 Kideny (100)
0.03–0.4 Liver(90) Kidney(10)
Unknown Kidney (100)
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Fig. 2. Time to recurrence of atrial ﬁbrillation (AF) in patients with paroxysmal and persistent atrial ﬁbrillation (AF) that received dronedarone and placebo. Abbreviations:
AF, atrial ﬁbrillation. Modiﬁed from Singh BN, et al. [16].
Amiodarone
(200 mg/day)
Sotalol or
Propafenine
Mean age (y.o) 65 65
CAD 19% 18%
Paroxysmal AF 49% 43%
Persistent AF 51% 57%
Rate of maintenance
of sinus rhythm
64% 61%
Rate of conversion
to permanent form 35% 38%
LVEF<50% 12% 12%
Mean LAD 41 mm 41 mm
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Amiodarone: 18%
Propafenone/Sotalol: 11% (p = 0.06)
Number 201 202
Atrial fibrillation with lasting for 10 minutes or more, and its history within recent 6 months,
except for heart failure and acute coronary syndrome .
Follow-up period
Fig. 1. Survival curve of patients free from recurrence of atrial ﬁbrillation (AF) as reported by the Canadian Trial of Atrial Fibrillation (CTAF). Abbreviations: aF, atrial
ﬁbrillation; CAD, coronary artery disease; LAD, left atrial dimension; LVEF, left ventricular ejection fraction. Modiﬁed from Roy D, et al. [14].
T. Komatsu / Journal of Arrhythmia 28 (2012) 162–169164analysis has indicated that dronedarone is slightly less effective
than amiodarone in preventing AF recurrence [18].
It is likely that the wide variability in the percentage of
patients successfully treated with antiarrhythmic drugs was
caused by differences in patient proﬁles among the studies. It
has been suggested that recurrence of AF is associated with aging
[19,20], duration of AF episodes [21,21], AF history [23], increased
left atrial dimension [21,22,24], the presence of underlying heart
disease (e.g., valvular and ischemic heart diseases) [21,25], and
circadian variation in AF onset (mixed AF type) [26], among other
factors. Moreover, patients in Western countries receive different
types of antiarrhythmic drugs at doses 1.5- to 2-fold higher than
the standard doses in Japan. The results of studies conducted in
Japan are summarized in the following section.
2.2. Results of Japanese studies
In a multi-center collaborative study in Japan using Cardio-
phone, a transtelephonic ECG monitoring system, the percentageof patients without AF recurrence after 1 month of treatment with
ﬂecainide was 9.4% and 39.4% at dosages of 100 and 200 mg/day,
respectively, indicating a dose-dependent effect [27]. It should be
noted that the methodology used to detect AF episodes will affect
the percentage of patients found to have no AF recurrence.
Another study reported that the addition of bepridil at low or
intermediate dosages (50–150 mg/day) to treatment regimens for
patients with paroxysmal AF refractory to Class I antiarrhythmic
drugs resulted in a decrease in the number of AF episodes to less
than 10% before the addition of bepridil [28].
In the Japanese Rhythm Management Trial for Atrial Fibrilla-
tion (J-RHYTHM) study, investigators in 182 institutions
registered 885 patients with paroxysmal AF to evaluate the
maintenance of sinus rhythm by antiarrhythmic drugs. The
percentage of patients who maintained sinus rhythm was 85%
during the ﬁrst 6–12 months, 82% at 24 months, and 70% after 36
months of treatment (Fig. 3). On the other hand, the percentage of
patients who maintained sinus rhythm during treatment with
rate control therapy was 71%, 66%, 63%, and 42% at 6, 12, 24, and
T. Komatsu / Journal of Arrhythmia 28 (2012) 162–169 16536 months of treatment, respectively, which were lower than
those obtained in patients undergoing rhythm control therapy
using antiarrhythmic drugs [29] (Fig. 3). In the J-RHYTHM study,
pilsicainide was used for 33% of patients, cibenzoline for
21%, propafenone for 12%, disopyramide for 9%, ﬂecainide for
8%, and bepridil for 7%; Class I antiarrhythmic drugs were the
most commonly used drug.
2.3. Treatment with antiarrhythmic drugs based on the relationship
between the autonomic nervous system and paroxysmal AF
The Guidelines for Pharmacotherapy of Atrial Fibrillation
published by the Japanese Circulation Society (JCS) in 2008
classify lone AF by the duration of AF episodes into either
paroxysmal AF (AF that terminates spontaneously within 7 day)
or persistent AF (AF that persists for longer than 7 day), and
recommend 5 Class Ia/Ic antiarrhythmic drugs for paroxysmal
AF and 3–4 Class III drugs for persistent AF as ﬁrst-line therapy
(Fig. 4A) [30]. However, although the JCS guidelines list many
antiarrhythmic drugs, there are no detailed descriptions of which
drugs are effective in particular patient populations. In contrast,
the guidelines for the management of atrial ﬁbrillation published
by the European Society of Cardiology (ESC), which were revised
in 2010, recommend the selection of appropriate drugs for
patients with lone AF and those with AF and relatively mild
underlying heart disease according to the involvement of the
autonomic nervous system in the pathophysiology of AF, as
suggested by the mode of onset of AF (Fig. 4B) [31]. In the ESC(%)
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Fig. 3. Survival curve of patients free from recurrence of paroxysmal atrial ﬁbrillation
(J-RHYTHM) study. Abbreviations: AF, atrial ﬁbrillation. Modiﬁed from Ogawa S, et al.guidelines, AF is classiﬁed by mode of onset into 3 types,
adrenergically mediated AF, vagally mediated AF, and undeter-
mined AF. It is recommended that when treating adrenergically
mediated AF physicians try beta-blockers ﬁrst, then sotalol, and
dronedarone last. The recommended ﬁrst-line therapy for vagally
mediated AF is disopyramide, while the recommended treatment
for undetermined AF includes dronedarone, ﬂecainide, propafe-
none, or sotalol as ﬁrst-line drugs. Amiodarone is the last choice
drug for all AF types. In Japan, researchers have evaluated the
efﬁcacy of antiarrhythmic regimens selected according to the
presumed relationship between AF episodes and the autonomic
nervous system, based on the time at which AF episodes occur. In
these studies, patients were classiﬁed by circadian variation in the
typical occurrence of AF episodes into the following categories:
diurnal AF (episodes occurring between 0700 and 1700, when the
sympathetic nervous system dominates), nocturnal AF (episodes
occurring between 1700 and 0700, when the parasympathetic
nervous system dominates), and mixed type AF (episodes occur-
ring irrespective of circadian variation), and the efﬁcacy of
antiarrhythmic drugs within these subgroups was investigated.
The efﬁcacy of disopyramide (300 mg/day) in preventing AF
recurrence after 24 months of treatment was signiﬁcantly higher
among patients with nocturnal AF than those with diurnal and
mixed AF [32] (Fig. 5A). Cibenzoline (300 mg/day) was signiﬁ-
cantly more effective in both the diurnal and nocturnal AF groups
than in the mixed AF group [33] (Fig. 5B). In a subanalysis of a
study in patients with recurrent AF refractory to antiarrhythmic
drugs, the efﬁcacy of pilsicainide (150 mg/day) [34] and ﬂecainide-up period
thm control therapy (N = 419)
e control therapy (N=404)
21.5years years 2.5years 3years
(AF) as reported by the Japanese Rhythm Management Trial for Atrial Fibrillation
[32].
Pilsicainide
Cibenzoline
Propafenone
Disopyramide
Flecainide
Paroxysmal
Lone AF Electrical Cardioversion
Rate control
Bepridil*
Persistent
Sotalol*
Amiodarone*First -line therapy
Short-lasting  AF
Second- or third-line therapy
Pulmonary vein
isolation
±Aprindine
Ablate & Pace
therapy
No or minimal structural heart disease
Adrenergcally mediated Undetermined
Dronedarone
Flecainide
Propafenone
Sotalol
β-blockers
Sotalol
Dronedarone Amiodarone
Vagally mediated
Disopyramide
Fig. 4. (A) The Guidelines for Pharmacotherapy of Atrial Fibrillation published by the Japanese Circulation Society (JCS) in 2008. Abbreviations: AF, atrial ﬁbrillation.
Modiﬁed from Ogawa S, et al. [29]. (B) The Guidelines for the Management of Atrial Fibrillation published by the European Society of Cardiology (ESC) in 2010. Modiﬁed
from Camm AJ, et al. [31].
T. Komatsu / Journal of Arrhythmia 28 (2012) 162–169166(150 mg/day) [35] in preventing AF recurrence at 12 months was
signiﬁcantly higher in patients with daytime AF than in those
with mixed AF (Figs. 5C and D). Watanabe et al. reported that
propafenone (450 mg/day) is effective in preventing recurrent
diurnal AF [36]. These results indicate that patients with noctur-
nal AF may respond well to anticholinergic drugs that block
muscarinic receptors, which are activated at night through
the parasympathetic nervous system; patients with diurnal AF
may respond better to drugs that block sodium or calcium
channels, which are activated during the daytime through the
sympathetic nervous system, or antiarrhythmic drugs that block
beta-receptors.
In 334 patients who were followed for 60735 months during
treatment with drugs selected on the basis of the relationship
between AF and the autonomic nervous system, the percentage
of paroxysmal AF patients who maintained sinus rhythm during
treatment was 92% at 12 months, 88% at 24 months, 85% at 36
months, 80% at 60 months, and 75% at 120 months. The incidence
of conversion to persistent AF despite rhythm control therapy was
demonstrated to be 2.5% per year [37]. Using the estimated
incidence of persistent AF among patients with AF, which was
calculated as 5.5% per year based on the natural history of AF in
Japanese patients [38], it was concluded that antiarrhythmic
drugs selected according to the time of onset of AF episodes can
prevent conversion to permanent AF in approximately 60% of
patients. In data from our institution, independent predictors of
pharmacological conversion to permanent AF in the presence
of rhythm control therapy in patients with paroxysmal atrialﬁbrillation included mixed AF type, asymptomatic AF, AF history,
left atrial dimension, and congestive heart failure, hypertension,
age 475 years, diabetes mellitus, and prior stroke (CHADS2)
score (Table 3).3. QOL and cardiovascular prognosis in patients with
paroxysmal AF
Paroxysmal AF is an arrhythmia that should be actively
treated and controlled, as it causes deterioration of QOL and
cardiovascular complications such as thromboembolism and
congestive heart failure (CHF) [39], and also decreases survival
in patients with impaired left ventricular function [40]. Evalua-
tion for QOL can be conducted using a comprehensive tool such
as the medical outcomes study short form health survey (SF-36)
or, speciﬁcally for underlying heart disease, the atrial ﬁbrillation
quality of life questionnaire (AFQLQ). According to large Western
clinical trials, there are no signiﬁcant differences in QOL
between patients treated with rhythm control therapy and those
treated with rate control when analyzed by SF-36 [41–43].
However, a comprehensive tool such as the SF036 is not always
suitable for the evaluation of QOL in patients with underlying
heart disease. On the other hand, AFQLQ is considered to be a
speciﬁc tool for the evaluation of limitation of daily life,
psychological anxiety, and general discomfort, including medi-
cation side-effects, in patients with AF [44]. The J-RHYTHM
study has demonstrated that QOL is superior for patients treated
Fig. 5. (A) Survival curve of patients free from recurrence of paroxysmal atrial ﬁbrillation (AF) that received disopyramide therapy on the basis of circadian variation.
Abbreviations: AF, atrial ﬁbrillation. Modiﬁed from Komatsu T, et al. [32]. (B) Survival curve of patients free from recurrence of paroxysmal atrial ﬁbrillation (AF) that
received cibenzoline therapy on the basis of circadian variation. Abbreviations: AF, atrial ﬁbrillation. Modiﬁed from Komatsu T, et al. [33]. (C) Survival curve of patients free
from recurrence of paroxysmal atrial ﬁbrillation (AF) receiving pilsicainide therapy on the basis of circadian variation. Abbreviations: AF, atrial ﬁbrillation. Modiﬁed from
Komatsu T, et al. [34]. (D) Survival curve of patients free from recurrence of paroxysmal atrial ﬁbrillation (AF) that received ﬂecainide therapy on the basis of circadian
variation. Abbreviations: AF, atrial ﬁbrillation. Modiﬁed from Komatsu T, et al. [35].
Table 3
Predictors for conversion to permanent AF in paroxysmal AF patients treated with
antiarrhythmic drugs therapy.
Variables Odds ratio (95% CI) P-value
Mixed AF onset 5.859 (1.999–17.17) 0.001
Symptomatic AF 0.261 (0.114–0.596) 0.001
AF history (months) 1.013 (1.004–1.021) 0.003
LAD (mm) 1.054 (1.002–1.110) 0.045
CHADS2 score 1.596 (1.001–2.266) 0.048
LVEF (%) 1.051 (0.998–1.092) 0.059
RAAS inhibitors 0.599 (0.253–1.422) 0.245
Age (yrs) 1.019 (0.984–1.055) 0.293
Dyslipidemia 0.158 (0.004–5.794) 0.315
Hypertension 0.645 (0.273–1.527) 0.319
LVDd (mm) 1.033 (0.966–1.103) 0.344
Statin 2.649 (0.085–82.19) 0.578
Diabetes mellitus 1.269 (0.458–3.517) 0.648
Underlying heart disease 1.100 (0.503–2.406) 0.811
Underlying pulmonary disease 1.204 (0.187–7.751) 0.845
Smoking habits 0.919 (0.388–2.178) 0.848
Gender (male) 1.077 (0.423–2.741) 0.877
(N¼505, mean follow up 50736 months).
Abbreviations: AF, atrial ﬁbrillation; RAAS, renin-angiotensin aldosterone system;
LVDd, left ventricular end-diastolic dimension; LAD, left atrial dimension; LVEF,
left ventricular ejection fraction.
T. Komatsu / Journal of Arrhythmia 28 (2012) 162–169 167with rhythm control therapy compared to those treated with
rate control therapy using AFQLQ in Japanese patients with
paroxysmal AF [29]. Another Japanese study has revealed thatreducing the incidence of AF recurrence is important for improv-
ing QOL in patients with paroxysmal AF [45].
In several Western reports from large-scale comparative stu-
dies and epidemiological surveys, there was no signiﬁcant differ-
ence in the incidence of thromboembolism between paroxysmal
and persistent AF patients [46,47]. Data from our institution
suggested that the incidence of cardiogenic thromboembolism
decreased when sinus rhythm was maintained without AF recur-
rence in patients with paroxysmal AF receiving rhythm control
therapy, even if inadequate anticoagulation therapy was given
(Table 4) [48]. Moreover, CHF is closely related to AF [49] and
plays an important role in the prognosis of paroxysmal AF
patients [50]. The mortality rate among AF patients with con-
gestive heart failure 1 year after initial diagnosis is relatively high,
between 13% and 20% in Western and countries including the
United States [51,52] and 7.3% in Japan [53]. In data from our
institute [54], the incidence of new-onset CHF at 1 year in
Japanese patients with paroxysmal AF receiving rhythm control
therapy was nearly 1.0–2.0%, and the independent predictors of
hospitalization for CHF were CHADS2 score, left ventricular ejec-
tion fraction, and underlying heart disease (Table 5). When
cardiovascular events included the composite of hospitalization
for thromboembolism, heart failure, and cardiovascular death, the
independent predictors of cardiovascular events in Japanese
patients with paroxysmal AF receiving rhythm control therapy
were also CHADS2 score, underlying heart disease, left ventricular
ejection fraction, conversion to persistent AF, and anticoagulant
therapy.
Table 4
Incidences and annual rates of ischemic stroke according to outcome of the antiar-
rhythmic drugs and antithrombotic therapy. Modiﬁed from Komatsu T, et al. [48].
No AF
recurrence
AF
recurrence
Permanent
AF
All patients 1/114 22/113 16/63
annual rate (%) 0.3 4.2nn 5.1nn
Without antithrombotic
therapy
0/62 12/50 10/16
annual rate (%) 0 5.1n 12.5n
With antithrombotic therapy 1/52 10/63 6/47
annual rate (%) 0.6 3.4n 2.6n
Aspirin 1/41 9/39 5/19
annual rate (%) 0.8 4.9n 5.2n
Warfarin 0/11 1/24 1/28
annual rate (%) 0 0.9 0.7
(N¼290, mean follow-up period; 50734 months).
n po0.05, No AF recurrence Group versus AF recurrence and Permanent AF Group.
nn po0.01,NoAFrecurrence Group versus AF recurrence and Permanent AF Group.
Table 5
Predictors for heart failure in patients with paroxysmal atrial ﬁbrillation according
to the antiarrhythmic drugs therapy.
Variables Odds ratio
(95% Conﬁdence interval)
P-value
CHADS2 score 3.239 (1.937–5.416) 0.001
LVEF (%) 0.957 (0.919–0.997) 0.033
Underlying heart disease 2.689 (1.001–7.132) 0.047
LVDd (mm) 0.923 (0.847–1.005) 0.066
Anticoagulant therapy 2.648 (0.921–7.612) 0.071
Age (yrs) 0.960 (0.912–1.010) 0.118
Conversion to chronic AF 2.300 (0.774–6.832) 0.134
RAAS inhibitors 2.146 (0.762–6.044) 0.148
Diabetes mellitus 0.690 (0.209–2.279) 0.543
Gender (male) 0.960 (0.251–2.360) 0.647
Statin 2.526 (0.553–11.53) 0.647
LAD (mm) 1.013 (0.942–1.088) 0.733
AF history (months) 0.998 (0.985–1.011) 0.757
Symptomatic AF 1.238 (0.305–5.031) 0.765
Underlying pulmonary disease 0.804 (0.076–8.541) 0.856
(N¼459 follow-up periods 50735months).
Abbreviations: AF, atrial ﬁbrillation; RAAS, renin angiotensin aldosterone system;
LVDd, left ventricular end-diastolic dimension; LAD, left atrial dimension; LVEF,
left ventricular ejection fraction. Modiﬁed from Komatsu T, et al. [54].
T. Komatsu / Journal of Arrhythmia 28 (2012) 162–1691684. Conclusion
The ultimate goal of antiarrhythmic drug therapy to maintain
sinus rhythm is to improve QOL and cardiovascular prognosis,
while ensuring the safety of antiarrhythmic drugs. Rhythm con-
trol therapy is an ideal method for preventing AF recurrence over
a long period in patients with paroxysmal AF. However, it should
be noted that aimless long-term treatment with Class I drugs may
have an adverse effect on cardiovascular prognosis in AF patients
with cardiac dysfunction [55]. Physicians should evaluate their
paroxysmal AF patients carefully and regularly for the risk of
thromboembolism, CHF, and cardiovascular death before consid-
ering the suitability of particular treatment regimens, as the use
of anticoagulants in combination with antiarrhythmic drugs is an
independent predictor for preventing cardiovascular events [56].Conﬂict of interest
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